Miyeon Kim1, Ji Ung Kim1, So Mi Kim2, HyunWoo Kim3. 1. Division of Nephrology, Department of Internal Medicine, Jeju National University, School of Medicine, Jeju National University Hospital, 15, Aran 13-gil, Jeju City, Jeju, 63241, Republic of Korea. 2. Division of Nephrology, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea. 3. Division of Nephrology, Department of Internal Medicine, Jeju National University, School of Medicine, Jeju National University Hospital, 15, Aran 13-gil, Jeju City, Jeju, 63241, Republic of Korea. andrewmanson@jejunuh.co.kr.
Abstract
PURPOSE: Hemodialysis vascular access dysfunction, mostly attributed to neointimal hyperplasia, is a major cause of morbidity and hospitalization in patients on hemodialysis. It has been reported that prostaglandin I2 has pleiotropic effects including anti-platelet, vasodilating, anti-inflammatory, and anti-atherogenic properties. In addition, several studies have shown that prostaglandin I2 can inhibit neointimal formation after vascular injury. This study aimed to investigate the effects of beraprost sodium, an oral synthetic analog of prostaglandin I2, on vascular access patency in patients on hemodialysis who experienced primary hemodialysis vascular access failure. METHODS:Fifty-five patients with end-stage renal disease who were on hemodialysis were prospectively selected for this study. Twenty-three patients were assigned to be treated with 120 µg/day of beraprost sodium, while remaining patients (n = 32) were assigned to a control group. The primary outcome was primary unassisted vascular access patency at 2 years. RESULTS: The incidence of primary unassisted patency at 2 years was 83% in the beraprost sodium group and 38% in the control group (p = 0.001). Analysis of covariables indicated that this effect occurred mainly as a result of beraprost sodium administration. No life-threatening adverse event or severe bleeding was recorded in any of the groups. CONCLUSIONS: Our data indicated that an oral prostaglandin I2 analog, beraprost sodium, is effective and safe for the maintenance of vascular access patency in patients on hemodialysis with primary vascular access failure.
RCT Entities:
PURPOSE:Hemodialysis vascular access dysfunction, mostly attributed to neointimal hyperplasia, is a major cause of morbidity and hospitalization in patients on hemodialysis. It has been reported that prostaglandin I2 has pleiotropic effects including anti-platelet, vasodilating, anti-inflammatory, and anti-atherogenic properties. In addition, several studies have shown that prostaglandin I2 can inhibit neointimal formation after vascular injury. This study aimed to investigate the effects of beraprost sodium, an oral synthetic analog of prostaglandin I2, on vascular access patency in patients on hemodialysis who experienced primary hemodialysis vascular access failure. METHODS: Fifty-five patients with end-stage renal disease who were on hemodialysis were prospectively selected for this study. Twenty-three patients were assigned to be treated with 120 µg/day of beraprost sodium, while remaining patients (n = 32) were assigned to a control group. The primary outcome was primary unassisted vascular access patency at 2 years. RESULTS: The incidence of primary unassisted patency at 2 years was 83% in the beraprost sodium group and 38% in the control group (p = 0.001). Analysis of covariables indicated that this effect occurred mainly as a result of beraprost sodium administration. No life-threatening adverse event or severe bleeding was recorded in any of the groups. CONCLUSIONS: Our data indicated that an oral prostaglandin I2 analog, beraprost sodium, is effective and safe for the maintenance of vascular access patency in patients on hemodialysis with primary vascular access failure.
Authors: T Fujita; Y Fuke; A Satomura; M Hidaka; I Ohsawa; M Endo; K Komatsu; H Ohi Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2001-10 Impact factor: 4.006
Authors: Charmaine E Lok; Louise Moist; Brenda R Hemmelgarn; Marcello Tonelli; Miguel A Vazquez; Marc Dorval; Matthew Oliver; Sandra Donnelly; Michael Allon; Kenneth Stanley Journal: JAMA Date: 2012-05-02 Impact factor: 56.272
Authors: Kevan R Polkinghorne; Kenneth K P Lau; Alan Saunder; Robert C Atkins; Peter G Kerr Journal: Nephrol Dial Transplant Date: 2006-07-19 Impact factor: 5.992
Authors: Bradley S Dixon; Gerald J Beck; Miguel A Vazquez; Arthur Greenberg; James A Delmez; Michael Allon; Laura M Dember; Jonathan Himmelfarb; Jennifer J Gassman; Tom Greene; Milena K Radeva; Ingemar J Davidson; T Alp Ikizler; Gregory L Braden; Andrew Z Fenves; James S Kaufman; James R Cotton; Kevin J Martin; James W McNeil; Asif Rahman; Jeffery H Lawson; James F Whiting; Bo Hu; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: N Engl J Med Date: 2009-05-21 Impact factor: 91.245
Authors: Yu Zhou; Ling Du; Bo Tu; Qiquan Lai; Xiaonan Du; Bo Xu; Fan Zhang; Mingdong Zhao; Ziming Wan; Jiajie Lai Journal: BMC Nephrol Date: 2018-12-27 Impact factor: 2.388
Authors: Sylwester P Rogula; Hubert M Mutwil; Aleksandra Gąsecka; Marcin Kurzyna; Krzysztof J Filipiak Journal: Cardiol J Date: 2020-11-17 Impact factor: 2.737